FDA Approves Kynmobi Sublingual Film to Treat Off Episodes in Parkinson’s

FDA Approves Kynmobi Sublingual Film to Treat Off Episodes in Parkinson’s
The U.S. Food and Drug Administration has approved Sunovion’s Kynmobi (apomorphine hydrochloride) as an on-demand sublingual treatment for off episodes, or times when medication wears off, in people with Parkinson’s disease. The medication, formerly known as APL-130277, is an apomorphine film that is placed under-the-tongue (sublingual administration) when patients start experiencing a worsening of their symptoms. It can be taken up to five ... read more
Source: Parkinson’s News TodayPublished on 2020-05-22By Ines Martins, PhD